News und Analysen
EQS-Adhoc: Zalando SE: Vereinbarung über Unternehmenszusammenschluss und öffentliches Übernahmeangebot an die Aktionäre der ABOUT YOU Holding SE.
EQS-Adhoc: Allianz SE: Änderung der Dividendenpolitik
EQS-Adhoc: Airbus SE: Airbus reports share buybacks for week starting 1 December 2025
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
Are things finally looking up for Merck (NYSE: MRK)? After being mostly southbound for the better part of the last two years, the pharmaceutical giant is showing signs of life. Over the past month
EQS-Adhoc: Airbus SE: Airbus updates 2025 commercial aircraft delivery target, maintains financial guidance
EQS-Adhoc: Airbus SE: Airbus reports share buybacks for week starting 24 November 2025
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
Over the past 18 months, Merck (NYSE: MRK) shares have been mostly southbound as the drugmaker encountered several headwinds. Its vaccine business isn't performing as well as expected, resulting in
EQS-News: Announcement pursuant to Art. 5 para 1 of Regulation (EU) No. 596/2014 in conjunction with Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 of the Commission (as amended or replaced from time
EQS-Adhoc: Deutsche Börse AG: Exclusive discussions regarding possible acquisition of Allfunds
Rivian's Lucrative Joint Venture Keeps Getting Better for Investors
Rivian Automotive (NASDAQ: RIVN) and Volkswagen's joint venture, known as RV Tech, was really a win for both sides. On one side, Rivian gained not only credibility for its software stack, but it
EQS-Adhoc: Airbus SE: Airbus reports share buybacks for week starting 17 November 2025
EQS-Adhoc: Deutsche Bank to issue Additional Tier 1 capital instruments
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price. Even worse, the pharmaceutical giant could face more issues ahead
EQS-Adhoc: Airbus SE: Airbus launches second tranche of previously-announced limited share buyback programme
EQS-News: Allianz achieves record results and expects a full-year operating profit of at least 17 billion euros
Why Shares of Rivian Are Driving Higher This Week
After racing more than 12% higher last week, Rivian Automotive (NASDAQ: RIVN) stock is continuing to climb higher this week. In addition to an upwardly revised price target, speculation that Rivian
EQS-Adhoc: Allianz SE: Allianz reports strong 9M results and increases outlook for full year 2025
1 Incredible Reason to Buy LLY's Stock in November
Drug giant Eli Lilly (NYSE: LLY) now has the best-selling drug on the planet. It's a GLP-1 dual receptor agonist called tirzepatide, which Lilly sells as Mounjaro for treating type 2 diabetes and
EQS-Adhoc: Siemens Aktiengesellschaft: Siemens plans to deconsolidate Siemens Healthineers
2 Stocks Down 13% and 34% to Buy Right Now
All things considered, broader equities have performed pretty well in 2025, with the S&P 500 up 14% since the beginning of the year. It seems so long ago that the index flirted with bear-market
EQS-News: Infineon Technologies AG: FY 2025 concluded in line with expectations. Moderate revenue growth expected in FY 2026 despite adverse currency impact, AI power revenue target significantly increased
EQS-News: E.ON continues growth course with investments in the energy transition
EQS-News: PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada